Bimeda® US Launches SpectoGard® Sterile Solution
Oakbrook Terrace, Illinois (July 19, 2023) – Bimeda Inc. is pleased to announce that SpectoGard (spectinomycin sulfate) sterile solution—which received FDA approval in September of 2022—is now available for veterinarians and cattle producers in the United States. SpectoGard Sterile Solution is the first bioequivalent, generic spectinomycin sulfate injectable solution that is approved for use in cattle for the treatment of bovine respiratory disease (pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
SpectoGard Sterile Solution contains the same active ingredient in the same concentration and dosage form as the approved brand name drug product, Adspec® (Zoetis, Inc., Kalamazoo, MI), which was first approved on January 28, 1998 but has been unavailable due to discontinued manufacturing for over 5 years.
“We are excited to provide veterinarians and producers an effective treatment option for the most common bacterial causes of BRD from a class of antimicrobials that hasn’t been used in many years. SpectoGard Sterile Solution is an aminocyclitol, which is closely related to the aminoglycosides except it doesn’t have the same potential side effects (such as nephrotoxicity) as the aminoglycosides do.” said Dr. Chris Thomsen, Senior Technical Services Veterinarian, Bimeda US.
SpectoGard Sterile Solution should be administered to cattle at a daily dose of 10 to 15 mg spectinomycin per kg of body weight (4.5 to 6.8 mL per 100 lbs. of body weight). Treatment should be administered at 24-hour intervals for 3 to 5 consecutive days. The meat withdrawal time for this product is 11 days.
SpectoGard Sterile Solution is available in 500 mL vials and requires a veterinary prescription for use.
To learn more, contact your veterinarian or go to www.BimedaUS.com/SpectoGardInj
